$5.10
-0.11-2.11%
Last update: Oct 23, 5:37 PM
Evommune Inc (EVMN) Stock Price, Quote, News & History
EVMNNYSE
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
You can purchase shares of Evommune (NYSE:EVMN) through any online brokerage.
Other companies in Evommune’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Evommune has a consensus price target of $31.11.
The stock price for Evommune (NYSE: EVMN) is $5.1 last updated October 23, 2026 at 5:37 PM EDT.
There are no upcoming dividends for Evommune.
Evommune does not have any upcoming earnings scheduled.
There is no upcoming split for Evommune.
Evommune is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic...
